论文部分内容阅读
[目的]观察内镜下胰管内支架置入术联合化瘀清胰汤治疗慢性胰腺炎(CP)的临床疗效。[方法]40例CP患者随机分为A组(12例)采用西医综合治疗;B组(13例)在西医综合治疗的基础上给予化瘀清胰汤,口服或鼻饲;C组(15例)在B组治疗的基础上行内窥镜逆行胆囊-胰腺造影(ERCP)术、胰管内支架置入术,疗程为7 d,观察3组患者治疗后临床症状、体征缓解时间及生化指标恢复正常时间,并随访半年。[结果]手术成功率100%,C组腹痛腹胀、恶心呕吐、脂肪泻3项症状积分显著优于A、B组,3组相比,C组总有效率(86.7%)明显高于A、B组(58.3%、76.9%)(P<0.05)。随访结果显示,C组患者体质量均有一定程度增加,治疗后随访体质量指数(BMI)(平均27.5±14.8)较治疗前(平均21.3±2.5)明显提高(P<0.05)。[结论]内镜下胰管内支架置入术联合清胰化瘀汤治疗CP,较单纯西医综合治疗与单纯中西医结合内科治疗疗效更好,更安全、可靠。
[Objective] To observe the clinical efficacy of endoscopic pancreatic duct stenting combined with Huayu Qingyitang in the treatment of chronic pancreatitis (CP). [Method] Forty patients with CP were randomly divided into group A (n = 12) treated with Western medicine. Group B (n = 13) was given Qiyu Qingyi Decoction orally or nasally on the basis of western medicine. ) Underwent endoscopic retrograde gallbladder-pancreas angiography (ERCP) and pancreatic duct stenting on the basis of group B. The course of treatment was 7 days. The clinical symptoms, the time of symptom relief and the biochemical indexes returned to normal after treatment in the three groups Time, and follow-up for six months. [Results] The total success rate of operation in group C was significantly higher than that in group A and B (100%). The total effective rate (86.7%) in group C was significantly higher than that in group A and B (86.7% Group B (58.3%, 76.9%) (P <0.05). The follow-up results showed that the body mass of patients in group C increased to some extent. After treatment, the body mass index (BMI) (mean 27.5 ± 14.8) was significantly higher than that before treatment (average 21.3 ± 2.5) (P <0.05). [Conclusion] Endoscopic pancreatic duct stenting combined with Qingyin Huayu Decoction in the treatment of CP is more effective, safer and more reliable than the combination of Western medicine and traditional Chinese medicine.